Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

View:
Post by klank37 on Jan 26, 2010 7:10pm

roche

Yes and I'm planning to invest all my money on them; they have some really good valium...
I actualy had a good laugh reading the reply, real funny ( bornready i know your a girl now ha ha ha you little one).
But on a more serious note. I had 150,000 shares of the thing now only 32,000 so it is not like I don't believe in isa I just think that  right now things are a little shake thats all.Just waving the flag for who ever is interested.
I truly talked to them and asked them about their money situation.....but still a few years away from approval.

That is my belief...but yes there is probably some upside for the short time sure.

Comment by macbethorfaust on Jan 26, 2010 8:49pm
”but still a few years away from approval”?? Do you mean psoriasis (US) and transplant?  Uvietis is targeted for approval by the summer (so say the fall)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities